MOLN News and Press, Molecular Partners AG From 03/14/24

2024-03-14 16:21:05 ET More on Molecular Partners Molecular Partners AG 2024 Q2 - Results - Earnings Call Presentation Molecular Partners says data from projected therapeutically active doses of MP0533 from Phase 1/2a trial to be presented in H1 Molecular Partners, O...

Research & Development Highlights Presented encouraging initial data from first four dosing cohorts of ongoing Phase 1/2a trial of MP0533 for patients with relapsed/refractory AML and AML/MDS at the ASH Annual Meeting, reporting an acceptable safety profile and initial anti-tumor ac...

AIA Group Limited ADR (AAGIY) is expected to report for Q4 2023 Bank of Georgia Group Plc (BDGSF) is expected to report for quarter end 2023-12-31 SecureWorks Corp. (SCWX) is expected to report $-0.15 for Q4 2024 Acacia Research Corporation (ACTG) is expected to report for quarter end...

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 01, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that it will issue its ...

2024-01-08 11:34:43 ET More on Molecular Partners Molecular Partners, Orano to collaborate on RDT therapies for cancer Seeking Alpha’s Quant Rating on Molecular Partners Historical earnings data for Molecular Partners Financial information for Molecula...

Tetra-specific T-cell engager MP0533 for patients with r/r AML and AML/MDS on track to deliver expanded clinical phase 1/2a data in H1 2024 Progress of Radio-DARPin Therapy (RDT) platform: Improved tumor to kidney uptake ratio enables expansion of RDT pipeline; first data on DLL3 as lea...

2024-01-07 12:00:45 ET More on AbbVie, Bristol-Myers, etc. AbbVie: Still Expensive Despite The Great M&A Acumen Bristol-Myers Squibb Company (BMY) Goldman Sachs Healthcare C-Suite Unscripted Conference (Transcript) Merck & Co., Inc. (MRK) Goldman Sachs Health...

2024-01-05 16:32:00 ET Molecular Partners ( NASDAQ: MOLN ) has entered into a collaboration agreement with Orano Med to develop novel Radio-DARPin therapeutics, or RDTs, for the treatment of cancer. Under the agreement, the companies will exclusively develop DLL3 as an RDT targe...

Collaboration leverages lead-based ( 212 Pb) alpha emitter expertise and supply of Orano Med with Molecular Partners’ leadership in DARPins for tumor-targeted delivery of radioactive payloads Co-Development agreement covers multiple oncology targets, including DLL3 ...

2024-01-04 16:19:31 ET Gainers: Molecular Partners ( MOLN ) +14% . Sutro Biopharma ( STRO ) +9% . Ribbon Communications ( RBBN ) +7% . Resources Connection ( RGP ) +7% . Pyxis Oncology ( PYXS ) +6% . Losers: 89bio ( ETN...